Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.

Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.

Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.

The present invention relates to a pharmaceutical composition containing a sesquiterpene derivative or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of muscle diseases.

This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

The present invention relates to methods of treating tumours comprising the localised administration, for example, intratumourally or topically, of an epoxytiglienone compound (as a monotherapy) to cancerous tumours to generate a systemic anticancer C abscopal (anenestic) and/or bystander effect.

The present invention relates to methods of treating tumours comprising the localised administration, for example, intratumourally or topically, of an epoxytiglienone compound (as a monotherapy) to cancerous tumours to generate a systemic anticancer C abscopal (anenestic) and/or bystander effect.

The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).

The present invention discloses compositions useful for treatment or prevention of Amyotrophic Lateral Sclerosis (ALS) or a related condition, and treatment methods thereof.